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INVITED COMMENT
In late December 1998, the community of vas-
cular practitioners became aware of a shortage of
the tissue-culture urokinase compound known as
Abbokinase (Abbott Laboratories, North Chicago,
Ill). Abbokinase, originally approved in 1978, is the
predominant form of urokinase in widespread use
throughout the United States and Canada. The rea-
son for the shortfall is now well known to clinicians
and many lay persons alike. The US Food and Drug
Administration (FDA) put a hold on the release of
Abbokinase on the basis of presumed deviations in
the Current Good Manufacturing Practice regula-
tions, guidelines that were developed to protect the
consumer (patient) from the administration of
unsafe products.
The FDA inspected Abbott’s manufacturing facili-
ty in North Chicago, Ill, in late 1998. Shortly there-
after, the FDA issued a letter to the company that
raised concerns over the manufacturing of Abbo-
kinase. The FDA directed Abbott to cease further
release of Abbokinase pending resolution of several
manufacturing issues. Foremost in this regard was con-
cern about the neonatal kidney cells that Abbott used
as a source for Abbokinase. The cells originated in
Cali, Columbia, and were obtained through a separate
company, BioWhittaker (Walkersville, Md). The cells
were from a population thought to be at high risk for
a variety of diseases, including tropical diseases. The
mothers of the potential donors were not screened on
a consistent basis. Although the cells themselves were
tested for human immunodeficiency virus, hepatitis B
virus, and hepatitis C virus (HCV), the test for HCV
was not validated to the FDA’s satisfaction. Further,
before use in the manufacturing process, infectious
contamination of the kidney cells may have occurred
as a result of the manner in which they were harvest-
ed, handled, and stored. Lastly, although a viral inac-
tivation procedure is used in production that substan-
tially inactivates human immunodeficiency virus,
hepatitis B virus, and HCV in most biologic products,
the procedure has variable effects on other infectious
agents and is not fully validated for viral inactivation
of Abbokinase. The FDA conceded that they were
unaware of any cases of infectious transmission by
Abbokinase but suggested that any connection
between the drug and such cases might have gone
unrecognized and unreported. On January 25, 1999,
the FDA issued an “Important Drug Warning” com-
munication to the medical community that outlined
the risks associated with Abbokinase and encouraged
prescribers to consider alternatives to its use.
As a result of efforts by Abbott, the members of
the Society of Cardiovascular and Interventional
Radiology, and the medical community at large, the
FDA released several lots of Abbokinase in early
1999. Abbott implemented additional testing of
Abbokinase lots, and neither Abbott’s nor the
FDA’s tests of finished lots detected the presence of
infectious contamination. Reovirus was, however,
found in three lots of in-process product. Reovirus is
an etiologic agent responsible for minor upper respi-
ratory and gastrointestinal illnesses. These lots were
not manufactured into finished Abbokinase, and, in
addition, the heat inactivation step performed dur-
ing further manufacturing would be predicted to
inactivate the virus. Additional lots have not been
released, and the Abbokinase shortage remains criti-
cal, but upper level discussions between Abbott and
the FDA are ongoing.
The urokinase story has been quite disconcerting
to vascular practitioners. The FDA issued a procla-
mation that severely impacted the availability of a
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drug important to the practice of a large body of
physicians without consulting representatives of that
specialty group. In fairness, there were informal
communications that suggest that the FDA was
interested in replacing drugs of human tissue origin
with recombinant agents. In fact, at least two man-
ufacturers did institute development plans for alter-
nate thrombolytic agents for use in peripheral arter-
ial occlusion. Specifically, a recombinant form of
urokinase, recombinant tissue plasminogen activa-
tor, and recombinant prourokinase were studied.
Unfortunately, the attempts to secure a lower
extremity arterial indication for these agents either
were unsuccessful or remain incomplete.
At this date, the development and execution of a
trial designed to gain a lower extremity indication for
a thrombolytic agent remain highly problematic. The
Center for Biologics Evaluation and Research
(CBER), the branch of the FDA with the responsibil-
ity for thrombolytic agents, presently requires the suc-
cessful completion of at least one, and sometimes two,
randomized clinical trials that compare the use of the
thrombolytic agent with a control group of patients
who undergo “standard medical treatment,” in this
case open surgical revascularization. The new therapy
must be superior to the standard therapy, with a 95%
degree of certainty. Alternatively, approval of the new
therapy is possible with the demonstration of equiva-
lence to the older treatment, but we must be 95% cer-
tain that the new therapy is not more than 5% worse
than the old one. Moreover, the primary endpoint
must be “clinically relevant” in any acceptable trial. In
other words, the primary endpoint must be some-
thing that is directly appreciated by the patient. Thus,
clot lysis, patency rate, or ankle-brachial indices are
not accepted as clinically relevant endpoints. Rather,
amputation-free survival rate has been the primary
endpoint most agreeable to CBER.
The assumption that surgical revascularization is
the only standard of care in 1999 is an opinion
unlikely to be shared by many in the medical com-
munity. In fact, most vascular practitioners believe
that Abbokinase is as much a standard of care as pri-
mary operative revascularization, and choices regard-
ing the most appropriate initial therapy depend on
the specific clinical presentation. If the FDA will
accept the premise that Abbokinase is an acceptable
standard of care for patients with lower extremity
peripheral arterial occlusion, the door would open
for a variety of well-designed trials that compare
newer agents to Abbokinase. The vascular communi-
ty would readily embrace such a position and could
be relied on to design, organize, and execute a vari-
ety of multicenter clinical trials to gain approval for
alternate thrombolytic agents. It seems that such a
change in the stance of the FDA would predictably
achieve the stated goal of replacing Abbokinase with
other agents.
On an optimistic note, CBER has recently been
quite open and helpful in forging new clinical trials
aimed at garnering approval for peripheral thrombol-
ysis. In the historical novel The Leopard, Guiseppe
Tomasi di Lampedusa wrote, “If we want things to
stay as they are, things will have to change.” The con-
tinued availability of peripheral thrombolysis is
dependent on the ability to alter our scientific com-
placency. We must collect sound data to prove beliefs
that heretofore have been based on little more than
anecdotal experience.
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